These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 6890637)
1. BehavioraL and biochemical changes caused by muscimol in mice withdrawN from haloperidol administration. Kuruvilla A; Fung YK; Uretsky NJ Neuropharmacology; 1982 Sep; 21(9):891-7. PubMed ID: 6890637 [TBL] [Abstract][Full Text] [Related]
2. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined. Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027 [TBL] [Abstract][Full Text] [Related]
3. Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines. Matsui Y; Kamioka T Naunyn Schmiedebergs Arch Pharmacol; 1978 Dec; 305(3):219-25. PubMed ID: 33340 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of striatal injections of dopaminergic, cholinergic and GABAergic drugs upon swimming behavior of rats. Vrijmoed-de Vries MC; Cools AR Brain Res; 1986 Jan; 364(1):77-90. PubMed ID: 3004649 [TBL] [Abstract][Full Text] [Related]
5. An in vivo method for testing GABAergic compounds. Fung YK; Novin-Baheran A; Bosh TK; Grassman DR Pharmacol Biochem Behav; 1982 Oct; 17(4):651-4. PubMed ID: 7178178 [TBL] [Abstract][Full Text] [Related]
6. The enhancement of the hypomotility induced by small doses of haloperidol in the phase of dopaminergic supersensitivity in mice. Masuda Y; Murai S; Saito H; Abe E; Fujiwara H; Kohori I; Itoh T Neuropharmacology; 1991 Jan; 30(1):35-40. PubMed ID: 2046878 [TBL] [Abstract][Full Text] [Related]
8. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment. Nomura Y; Komori T; Okuda S; Segawa T Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682 [TBL] [Abstract][Full Text] [Related]
9. Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Lannes B; Micheletti G; Warter JM; Kempf E; Di Scala G Neurosci Lett; 1991 Jul; 128(2):177-81. PubMed ID: 1945038 [TBL] [Abstract][Full Text] [Related]
10. Baclofen and muscimol: behavioural and neurochemical sequelae of unilateral intranigral administration and effects on 3H-GABA receptor binding. Waddington JL; Cross AJ Naunyn Schmiedebergs Arch Pharmacol; 1979 Apr; 306(3):275-80. PubMed ID: 471079 [TBL] [Abstract][Full Text] [Related]
11. Is dopamine involved in the hyperactivity produced by injections of muscimol into the median raphe nucleus? Wirtshafter D; Klitenick MA; Asin KE Pharmacol Biochem Behav; 1988 Jul; 30(3):577-83. PubMed ID: 3211966 [TBL] [Abstract][Full Text] [Related]
12. Effect of muscimol, a central GABA receptor agonist, on the catalepsy, striatal homovanillic acid increase, and analgesia induced by pilocarpine in rats. Naik SR; Kelkar MR; Amladi SR; Sheth UK Psychopharmacology (Berl); 1981; 74(4):393-4. PubMed ID: 6794090 [TBL] [Abstract][Full Text] [Related]
13. Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Hillegaart V; Ahlenius S; Magnusson O; Fowler CJ Pharmacol Biochem Behav; 1987 May; 27(1):159-64. PubMed ID: 3615537 [TBL] [Abstract][Full Text] [Related]
14. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320 [TBL] [Abstract][Full Text] [Related]
15. Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing. Csernansky JG; Bellows EP; Barnes DE; Lombrozo L Psychopharmacology (Berl); 1990; 101(4):519-24. PubMed ID: 2388975 [TBL] [Abstract][Full Text] [Related]
16. Behavioral activation by stimulation of a GABAergic mechanism in the preoptic area of rat. Osborne PG; Mataga N; Onoe H; Watanabe Y Neurosci Lett; 1993 Aug; 158(2):201-4. PubMed ID: 8233095 [TBL] [Abstract][Full Text] [Related]
17. Oral behaviour induced by intranigral muscimol is unaffected by haloperidol but abolished by large lesions of superior colliculus. Taha EB; Dean P; Redgrave P Psychopharmacology (Berl); 1982; 77(3):272-8. PubMed ID: 6812150 [TBL] [Abstract][Full Text] [Related]
18. Uric acid levels and dopamine transmission in rat striatum: diurnal changes and effects of drugs. O'Neill RD Brain Res; 1990 Jan; 507(2):267-72. PubMed ID: 2337766 [TBL] [Abstract][Full Text] [Related]
19. Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat. Deutsch SI; Halperin R; Stanley M; Davis KL Neurochem Res; 1985 Apr; 10(4):491-8. PubMed ID: 2582289 [TBL] [Abstract][Full Text] [Related]
20. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. See RE Neurosci Lett; 1991 Aug; 129(2):265-8. PubMed ID: 1720879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]